TN2009000381A1 - C5 antigens and uses thereof - Google Patents

C5 antigens and uses thereof

Info

Publication number
TN2009000381A1
TN2009000381A1 TNP2009000381A TN2009000381A TN2009000381A1 TN 2009000381 A1 TN2009000381 A1 TN 2009000381A1 TN P2009000381 A TNP2009000381 A TN P2009000381A TN 2009000381 A TN2009000381 A TN 2009000381A TN 2009000381 A1 TN2009000381 A1 TN 2009000381A1
Authority
TN
Tunisia
Prior art keywords
inhibitor
treatment
antigens
complement component
ocular
Prior art date
Application number
TNP2009000381A
Other languages
English (en)
Inventor
Braydon Charles Guild
Mark Taylor Keating
Mariusz Milik
Dmitri Mikhailov
Michael Roguska
Igor Splawski
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000381A1 publication Critical patent/TN2009000381A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
TNP2009000381A 2007-03-22 2009-09-18 C5 antigens and uses thereof TN2009000381A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89640807P 2007-03-22 2007-03-22
PCT/EP2008/053321 WO2008113834A2 (fr) 2007-03-22 2008-03-19 Antigènes c5 et leurs utilisations

Publications (1)

Publication Number Publication Date
TN2009000381A1 true TN2009000381A1 (en) 2010-12-31

Family

ID=39672693

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000381A TN2009000381A1 (en) 2007-03-22 2009-09-18 C5 antigens and uses thereof

Country Status (17)

Country Link
US (1) US20100166748A1 (fr)
EP (1) EP2129681A2 (fr)
JP (1) JP2010521194A (fr)
KR (1) KR20100015773A (fr)
CN (1) CN101679486A (fr)
AU (1) AU2008228247A1 (fr)
BR (1) BRPI0809105A2 (fr)
CA (1) CA2680760A1 (fr)
CL (1) CL2008000803A1 (fr)
EA (1) EA200901211A1 (fr)
IL (1) IL201020A0 (fr)
MA (1) MA31351B1 (fr)
MX (1) MX2009010181A (fr)
TN (1) TN2009000381A1 (fr)
TW (1) TW200848076A (fr)
WO (1) WO2008113834A2 (fr)
ZA (1) ZA200906374B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US8703136B2 (en) 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
RU2012102021A (ru) * 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. Биспецифические антитела, которые связываются с белками комплемента
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
ES2606134T3 (es) 2011-07-29 2017-03-22 Andritz S.A.S. Centrifugador y miembro de orificio de descarga de centrifugador para reducción de potencia
EP2583957A1 (fr) 2011-10-18 2013-04-24 LANXESS Deutschland GmbH Butène linéaire à partir d'isobutanol
WO2013126006A1 (fr) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides se fixant au composant c5 du complément humain
US10010513B2 (en) * 2012-05-25 2018-07-03 Novartis Ag Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
EP2975055A4 (fr) * 2013-01-31 2016-11-02 Univ Seoul Nat R & Db Found Anticorps anti-c5 et méthode de prévention et de traitement de maladies liées au complément
SI2970974T1 (sl) 2013-03-14 2017-12-29 Alnylam Pharmaceuticals, Inc. Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe
EP4223317A3 (fr) 2014-06-12 2023-09-27 RA Pharmaceuticals, Inc. Modulation de l'activité du complément
WO2016040589A1 (fr) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant le composant du complément c5 et leurs méthodes d'utilisation
WO2016081314A1 (fr) 2014-11-17 2016-05-26 Alexion Pharmaceuticals, Inc. Stratégie d'évaluation et de gestion des risques impliquant des suivis de patients quant à un inhibiteur du complément
LT3233921T (lt) 2014-12-19 2021-12-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antikūnai ir panaudojimo būdai
EP3988110A1 (fr) 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulateurs d'activité complémentaire
MX2018007352A (es) 2015-12-16 2019-05-16 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
TWI747936B (zh) * 2015-12-18 2021-12-01 日商中外製藥股份有限公司 抗ｃ５抗體及使用方法
US20190225678A1 (en) * 2016-06-07 2019-07-25 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
UA126561C2 (uk) * 2016-06-17 2022-11-02 Чугаі Сейяку Кабусікі Кайся Застосування антитіла проти с5
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
US20190328854A1 (en) * 2016-08-29 2019-10-31 The Cleveland Clinic Foundation C5 immunization for autologous anti-c5 antibody production
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
IL269122B1 (en) * 2017-03-06 2024-03-01 Univ Pennsylvania Antibodies against C5 and their uses
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
PL3612208T3 (pl) 2017-04-21 2023-07-24 Volution Immuno Pharmaceuticals Sa Coversin do leczenia autoimmunologicznych chorób pęcherzowych

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
WO2003078457A1 (fr) * 2002-03-19 2003-09-25 Cincinnati Children's Hospital Medical Center Muteines d'anaphylatoxine c5a, molecules d'acides nucleiques codant pour ces muteines et utilisations pharmaceutiques des muteines d'anaphylatoxine c5a
DK2860251T3 (en) * 2004-02-12 2018-06-06 Archemix Llc APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES
KR20170002684A (ko) * 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도

Also Published As

Publication number Publication date
EP2129681A2 (fr) 2009-12-09
IL201020A0 (en) 2010-05-17
TW200848076A (en) 2008-12-16
MA31351B1 (fr) 2010-05-03
WO2008113834A3 (fr) 2009-03-05
EA200901211A1 (ru) 2010-04-30
ZA200906374B (en) 2010-05-26
MX2009010181A (es) 2009-12-04
JP2010521194A (ja) 2010-06-24
KR20100015773A (ko) 2010-02-12
US20100166748A1 (en) 2010-07-01
CN101679486A (zh) 2010-03-24
CA2680760A1 (fr) 2008-09-25
WO2008113834A2 (fr) 2008-09-25
AU2008228247A1 (en) 2008-09-25
BRPI0809105A2 (pt) 2019-09-10
CL2008000803A1 (es) 2008-10-03

Similar Documents

Publication Publication Date Title
TN2009000381A1 (en) C5 antigens and uses thereof
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CA2711696C (fr) Compositions therapeutiques utilisees pour le traitement des affections inflammatoires oculaires
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SMT201600182B (it) Ligandi sigma per l'uso nella prevenzione e/o nel trattamento del dolore post-operatorio
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX357820B (es) Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EP4275752A3 (fr) Traitement d'addiction et de troubles de contrôle des impulsions au moyen d'inhibiteurs de la pde7
MX2007010752A (es) Usos oftalmicos de moduladores de receptor s1p.
JO3358B1 (ar) معالجات حساسية العيون
WO2014179568A3 (fr) Implant oculaire à deux couches
CA2871774C (fr) Utilisation de n-acetylcysteine amide dans le traitement de maladies et de lesions
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2009004134A (es) Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
IN2014DN08385A (fr)
UA94049C2 (ru) Применение ингибиторов glepp-1 для лечения аутоиммунных и/или воспалительных расстройств
WO2011041325A3 (fr) Procédés et compositions pour traitement de troubles viraux
MX2010003615A (es) Tratamiento de desordenes neurologicos.
PH12014500538A1 (en) Methods and compositions for treating leukemia
NZ628130A (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors